Overexpression of RAC1 correlates with poor prognosis in breast cancer cells27, and the pharmacologic reduction or knockdown of V-ATPase activity significantly reduce migration of invasive tumor cells in vitro preventing activation of EGFR and RAC116. Here, RAC1 is linked to breast cancer.